Overview

Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Daridorexant in Subjects Aged 10 to < 18 Years With Insomnia Disorder

Status:
Not yet recruiting
Trial end date:
2023-08-14
Target enrollment:
Participant gender:
Summary
This study assesses the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Idorsia Pharmaceuticals Ltd.